PROTAC

3-tert-Butyl-4-methoxyphenol serves as a PROTAC linker, facilitating targeted protein degradation. This compound exhibits unique biological activity, including insecticidal effects, and has been shown to enhance the activities of glutathione S-transferase and epoxide hydrolase in liver and forestomach tissues of A/HeJ mice. Its ability to regulate carcinogen metabolism makes it a valuable tool for research applications in cellular signaling and toxicology studies.

Cis-ethyl (1R,2S)-2-cyanocyclopropane-1-carboxylate is a versatile PROTAC linker designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates the selective degradation of target proteins through the ubiquitin-proteasome system. Its unique structural features allow for enhanced binding specificity and efficacy in targeted protein degradation research applications.

1,3-Dibromo-5,5-dimethylhydantoin serves as an efficient alkyl chain-based PROTAC linker, facilitating the development of proteolysis-targeting chimeras (PROTACs). Its unique structure enables selective degradation of target proteins, making it a valuable tool in chemical biology research. This compound is crucial for researchers focused on novel therapeutic strategies involving targeted protein degradation.

TRI-611 is an orally active molecular glue degrader that targets the anaplastic lymphoma kinase (ALK). It forms a ternary complex with the substrate receptor CRBN, leading to polyubiquitination and subsequent degradation of ALK, including resistant fusion proteins. TRI-611 effectively inhibits ALK-mediated downstream signaling and exhibits anti-proliferative effects in ALK-positive cancer cells. Preclinical studies demonstrate its capability to induce regression of ALK-positive non-small cell lung cancer tumors, making it a valuable tool for research into TKI-refractory tumors and central nervous system metastases.

Thalidomide-5-F-6-piperidinylpiperazin is a ligand for E3 ligase-linker conjugates and plays a crucial role in the synthesis of PROTAC CDK9 degrader-9. This compound facilitates targeted protein degradation, making it a valuable tool for studies on cellular signaling pathways and protein regulation. Researchers can utilize this reagent to explore therapeutic approaches in cancer and other diseases by modulating the activity of CDK9 and related targets.

PROTAC CDK2-pRb degrader-1 is an orally active PROTAC that targets cyclin-dependent kinase 2 (CDK2) for degradation. This compound effectively inhibits the phosphorylation of retinoblastoma protein (Rb) at serine 807/811 by promoting the ubiquitination and proteasomal degradation of CDK2. Demonstrating significant biological activity with EC50 values of 12 nM and 125 nM in human cells, PROTAC CDK2-pRb degrader-1 is particularly useful in research focused on CCNE1-amplified cancers, including ovarian, gastric, and breast cancers, as it inhibits tumor growth and induces tumor stasis in xenograft models.

PSP-0119 is a highly selective PROTAC degrader targeting IRAK4, demonstrating an IC50 of 2.83 nM. This compound effectively inhibits IRAK4 kinase activity, NF-κB signaling, and IL-1β-induced IRAK4 phosphorylation. Notably, PSP-0119 induces degradation of IRAK4 specifically in FLT3-mutant acute myeloid leukemia (AML) cell lines while sparing FLT3-wild-type AML cells and normal bone marrow. It serves as a valuable tool for research into the mechanisms underlying AML, particularly in targeting aberrant IRAK4 activity.

PROTAC SMARCA2/4 degrader-40 is a specific degrader targeting SMARCA2 and SMARCA4. It demonstrates potent degradation activity in HeLa cells, with a DC50 value of less than 0.1 nM. This compound is particularly useful for investigating cancers linked to SMARCA2/SMARCA4 abnormalities or mutations within the SWI/SNF complex, facilitating insights into their role in tumorigenesis.

1,6-Diiodohexane is a bifunctional linker designed for use in PROTAC (Proteolysis Targeting Chimeras) synthesis. Its unique structure facilitates the conjugation of target proteins to E3 ligases, enhancing the recruitment and degradation of specific proteins within the cell. This compound is valuable for researchers investigating targeted protein degradation mechanisms and developing novel therapeutics in protein homeostasis studies.

trans-1,4-Cyclohexanediamine serves as a versatile PROTAC linker, facilitating the development of targeted protein degradation tools. Its unique structure enhances the efficiency of PROTACs by promoting the selective degradation of target proteins via the ubiquitin-proteasome pathway. This compound is essential for researchers investigating novel therapeutic strategies in cancer and other diseases through protein modulation.